Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trial

OBJECTIVES: To evaluate the long-term efficacy and safety of canakinumab to treat patients with colchicine-resistant familial Mediterranean fever (crFMF) during Epoch 4 (weeks 41 to 113) of the CLUSTER study. METHODS: Patients received open-label canakinumab 150 or 300 mg, every 4 or 8 weeks during...

Descripción completa

Detalles Bibliográficos
Autores principales: Ozen, Seza, Ben-Cherit, Eldad, Foeldvari, Ivan, Amarilyo, Gil, Ozdogan, Huri, Vanderschueren, Steven, Marzan, Katherine, Kahlenberg, J Michelle, Dekker, Elise, De Benedetti, Fabrizio, Koné-Paut, Isabelle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Autoinflammatory Disorders
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7509527/
https://www.ncbi.nlm.nih.gov/pubmed/32571870
http://dx.doi.org/10.1136/annrheumdis-2020-217419

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7509527/
https://www.ncbi.nlm.nih.gov/pubmed/32571870
http://dx.doi.org/10.1136/annrheumdis-2020-217419

Ejemplares similares